Vaxcyte
PCVX
331 hedge funds and large institutions have $9.71B invested in Vaxcyte in 2026 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 132 increasing their positions, 102 reducing their positions, and 50 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 102
3% more capital invested
Capital invested by funds: $9.44B → $9.71B (+$274M)
2% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 50
1% less funds holding
Funds holding: 336 → 331 (-5)
11.9% less ownership
Funds ownership: 124.15% → 112.26% (-12%)
36% less funds holding in top 10
Funds holding in top 10: 22 → 14 (-8)
45% less call options, than puts
Call options by funds: $131M | Put options by funds: $238M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$237M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$109M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$75.3M |
| 4 |
BlackRock
New York
|
+$59.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$49.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$145M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$73.3M |
| 3 |
Jennison Associates
New York
|
-$66.4M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$63.7M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$57.8M |
PCVX Hedge Fund Activity: Q2 2026 in Review
331 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q2 2026, worth a combined $9.71B — up 2.9% from $9.44B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of PCVX and 49 opened new positions — a net loss of 1 holder — while 102 trimmed existing stakes and 132 added.
The largest buyer was Fidelity Investments, adding an estimated $237M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $145M.
- 331 institutional investors held Vaxcyte (PCVX) as of Q2 2026, down from 336 in Q1 2026.
- Funds reported $9.71B of Vaxcyte stock for Q2 2026, up 2.9% quarter-over-quarter.
- 49 funds opened new Vaxcyte positions in Q2 2026 and 50 closed out, a net change of -1 holder.
- The largest Vaxcyte buyer in Q2 2026 was Fidelity Investments, an estimated $237M added.
- The largest Vaxcyte seller in Q2 2026 was Paradigm Biocapital Advisors, an estimated $145M sold.
Based on aggregated 13F filings for Q2 2026.